Ariad celebrates early ponatinib win, but investors recoil over black box
This article was originally published in Scrip
Executive Summary
Not just Christmas, but spring came early for Ariad Pharmaceuticals on 14 December, as the US FDA granted its blessing for the Cambridge, Massachusetts biotech to market Iclusig (ponatinib) as a treatment for adults with chronic, accelerated or blast phase chronic myeloid leukemia (CML) resistant or intolerant to prior tyrosine-kinase inhibitors (TKIs) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) resistant or intolerant to prior TKIs.